Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model

• Published in: PloS one Vol. 16; no. 3; p. e0247990
• Main Authors: Baldwin, Susan L., Reese, Valerie A., Larsen, Sasha E., Beebe, Elyse, Guderian, Jeff, Orr, Mark T., Fox, Christopher B., Reed, Steven G., Coler, Rhea N.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 11.03.2021; Public Library of Science (PLoS)
• Subjects: Analysis; Antigens; Biology and Life Sciences; Care and treatment; Children; Cholesterol; Diagnosis; Editing; Global health; Human subjects; Immune response; Immunization; Infectious diseases; Informed consent; Lipids; Medicine and Health Sciences; Mycobacterium tuberculosis; Properties; Proteins; Public health; Research and Analysis Methods; TLR4; Tuberculosis; Tuberculosis vaccines; Vaccines; United States; United States > US
• DOI: 10.1371/journal.pone.0247990
• ISSN: 1932-6203

An estimated 10 million people developed tuberculosis (TB) disease in 2019 which underscores the need for a vaccine that prevents disease and reduces transmission. The aim of our current studies is to characterize and test a prophylactic tuberculosis vaccine comprised of ID93, a polyprotein fusion antigen, and a liposomal formulation [including a synthetic TLR4 agonist (glucopyranosyl lipid adjuvant, GLA) and QS-21] in a preclinical mouse model of TB disease. Comparisons of the ID93+GLA-LSQ vaccines are also made to the highly characterized ID93+GLA-SE oil-in-water emulsion adjuvant, which are also included these studies. The recent success of vaccine candidate M72 combined with adjuvant AS01 E (GlaxoSmithKline Biologicals) in reducing progression to active disease is promising and has renewed excitement for experimental vaccines currently in the TB vaccine pipeline. The AS01 E adjuvant contains monophosphoryl lipid A (MPL) and QS-21 (a saponin) in a liposomal formulation. While AS01 E has demonstrated potent adjuvant activity as a component of both approved and experimental vaccines, developing alternatives to this adjuvant system will become important to fill the high demand envisioned for future vaccine needs. Furthermore, replacement sources of potent adjuvants will help to supply the demand of a TB vaccine [almost one-quarter of the world’s population are estimated to have latent Mycobacterium tuberculosis (Mtb) according to the WHO 2019 global TB report], addressing (a) cost of goods, (b) supply of goods, and (c) improved efficacy of subunit vaccines against Mtb. We show that both ID93+GLA-SE (containing an emulsion adjuvant) and ID93+GLA-LSQ (containing a liposomal adjuvant) induce ID93-specific TH1 cellular immunity including CD4+CD44+ T cells expressing IFNγ, TNF, and IL-2 (using flow cytometry and intracellular cytokine staining) and vaccine-specific IgG2 antibody responses (using an ELISA). In addition, both ID93+GLA-SE and ID93+GLA-LSQ effectively decrease the bacterial load within the lungs of mice infected with Mtb. Formulations based on this liposomal adjuvant formulation may provide an alternative to AS01 adjuvant systems.